German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit
The German Court ruled in favor of the generic competitor in the case of
The compound patent for Alimta in
"We strongly disagree with the ruling by the
Harrington continued, "Although Alimta's compound patent remains in force and is expected to provide exclusivity in
In
Lilly's vitamin regimen patent was upheld in a prior ruling by the
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding Germany Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any appeal. Also, the company cannot predict whether generic pemetrexed will be marketed prior to the resolution of this litigation. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the
Alimta® (pemetrexed, Lilly)
Refer to:
+1 317-277-6524; lauren_zierke@lilly.com;
+49 6172 273-2738; pressestelle@lilly.com;
+1 317-655-6874; johnson_philip_l@lilly.com;
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/german-court-rules-against-lilly-in-alimta-vitamin-regimen-patent-lawsuit-300046635.html
SOURCE
News Provided by Acquire Media